rupiya.io
⠋Loading...
0%
❯ Evaluating quality metrics...
Akums Drugs and Pharmaceuticals Ltd is a Drug Manufacturers - Specialty & Generic company listed on NSE. The page combines exchange quotes, financial statements, shareholding, filings, and news so investors can review the business in one place.
Akums Drugs and Pharmaceuticals Ltd makes money through Domestic formulations, Exports and regulated markets, Specialty or institutional sales in Drug Manufacturers - Specialty & Generic. Revenue quality depends on demand growth, margin discipline, balance-sheet strength, and the company's ability to defend its position within Pharma.
Create a free account to view momentum, moving averages, and delivery signals.
Upgrade to view volatility, drawdown, factor, and risk metrics.
| Period | Mar 2016 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|
| Sales | ₹1,464 Cr | ₹1,651 Cr | ₹2,414 Cr | |||||
| Expenses | ₹1,340 Cr | ₹1,507 Cr | ₹2,240 Cr | |||||
| Operating Profit | ₹124 Cr | ₹144 Cr | ₹174 Cr | |||||
| OPM % | 8.0% | 9.0% | 7.0% | |||||
| Other Income | ₹6 Cr | ₹6 Cr | ₹26 Cr | |||||
| Depreciation | ₹31 Cr | ₹38 Cr | ₹67 Cr | |||||
| Interest | ₹23 Cr | ₹22 Cr | ₹20 Cr | |||||
| Profit Before Tax | ₹77 Cr | ₹89 Cr | ₹114 Cr | |||||
| Tax | ₹77 Cr | ₹89 Cr | ₹114 Cr | |||||
| Net Profit | ₹43 Cr | ₹61 Cr | ₹44 Cr | |||||
| EPS (₹) | 366.6 | 523.2 | 335.6 | |||||
| Dividend Payout % | 0% | 0% | 0% |
Register free to see 5 more years.
| Quarter | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | ₹970 Cr | ₹1,181 Cr | ₹1,083 Cr | ₹944 Cr | |||||||
| Expenses | ₹1,095 Cr | ₹1,029 Cr | ₹989 Cr | ₹941 Cr | |||||||
| Operating Profit | ₹-125 Cr | ₹152 Cr | ₹93 Cr | ₹3 Cr | |||||||
| OPM % | -13.0% | 13.0% | 9.0% | 0.0% | |||||||
| Depreciation | ₹30 Cr | ₹30 Cr | ₹32 Cr | ₹34 Cr | |||||||
| Interest | ₹12 Cr | ₹14 Cr | ₹12 Cr | ₹12 Cr | |||||||
| Net Profit | ₹-187 Cr | ₹33 Cr | ₹195 Cr | ₹-39 Cr | |||||||
| EPS (₹) | -13.2 | 2.2 | 13.5 | -2.9 |
Register free to see 7 more quarters.
| Period | Mar 2016 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Liabilities | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Equity Capital | ₹1 Cr | ₹1 Cr | ₹1 Cr | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Reserves | ₹493 Cr | ₹628 Cr | ₹721 Cr | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Borrowings | ₹255 Cr | ₹213 Cr | ₹175 Cr | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Other Liabilities | ₹293 Cr | ₹318 Cr | ₹1,140 Cr | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Total Liabilities | ₹1,042 Cr | ₹1,161 Cr | ₹2,037 Cr | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Assets | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Fixed Assets | ₹444 Cr | ₹501 Cr | ₹645 Cr | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Investments | ₹0 Cr | ₹18 Cr | ₹6 Cr | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Receivables | — | — | — | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Inventory | — | — | — | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Cash & Equivalents | — | — | — | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Other Assets | ₹598 Cr | ₹632 Cr | ₹1,329 Cr | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Total Assets | ₹1,042 Cr | ₹1,161 Cr | ₹2,037 Cr | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Register free to see 5 more years.
| Period | Operating | Investing | Financing | Net Cash Flow |
|---|---|---|---|---|
| Mar 2016 | ₹72 Cr | ₹-150 Cr | ₹66 Cr | — |
| Mar 2020 | ₹89 Cr | ₹-123 Cr | ₹37 Cr | — |
| Mar 2021 | ₹28 Cr | ₹-190 Cr | ₹233 Cr | — |
| Mar 2022 | ||||
| Mar 2023 | ||||
| Mar 2024 | ||||
| Mar 2025 | ||||
| Mar 2026 |
Register free to see 5 more years.
No dividend history available.
No corporate actions recorded.
| Company | M.Cap | P/E | ROE | 1Y Return |
|---|---|---|---|---|
| Sun Pharmaceutical Industries Ltd | ₹4,51,075 Cr | 41.3 | 0.00% | +8.45% |
| Dr Reddys Laboratories Ltd | ₹1,11,310 Cr | 19.7 | +11.84% | +8.74% |
| Cipla Ltd | ₹1,15,638 Cr | 25.5 | +11.74% | -5.78% |
| Apollo Hospitals Enterprise Ltd | ₹1,16,201 Cr | 64.5 | 0.00% | +7.74% |
| Divis Laboratories Ltd | ₹1,79,486 Cr | 72.5 | 0.00% | +3.69% |
Create a free account to see institutional ownership snapshots.
Create a free account to view recent director and promoter trades.
Create a free account to view recent institutional deal activity.
Create a free account to view analyst estimate summaries.
Create a free account to view ESG risk and governance summaries.
Upgrade to view issuer ratings, instruments, outlooks, and rating history.
rupiya.io is for research and education only. Metrics shown are not investment advice. Validate with SEBI-regulated disclosures before acting.